ABT

Abbott Laboratories (ABT +0.54%) primarily generates its revenue by researching, developing, manufacturing, and distributing a diverse portfolio of medical devices, diagnostic test systems, nutritional formulas, and generic pharmaceutical products across international healthcare networks.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Pfizer has a deep pipeline that could help improve its approved lineup and financial results over the medium term. Abbott Laboratories' core medical device business remains strong, and the company has attractive opportunities elsewhere.

Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank the Dividend Kings using my 9F Quality Scores, blending qualitative and quantitative factors for a robust, investment-grade assessment. ADP stands out as the best total-return candidate. It is undervalued, high-quality, and offering a strong projected dividend growth rate and Adjusted Chowder Number.

Wall Street analysts have raised price targets on Abbott, citing accelerating growth in its Medical Devices segment. Abbott's diabetes, electrophysiology, and new Exact Sciences cancer-screening businesses are driving stronger sales and earnings.

ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Abbott (ABT) closed the most recent trading day at $103.09, moving +1.12% from the previous trading session.

Abbott Laboratories ​has ‌agreed to ​pay ​more than $384 million ⁠to ​settle ​allegations related to ​contaminated ​infant formula, the ‌U.S. ⁠Justice Department said ​on ​Monday.

Settlement does not represent any finding of fault or liability As the government has previously indicated, it has closed its criminal investigation on this matter Tests by government regulators of unopened product from the homes of the infants under investigation at the time of the 2022 recall were negative for Cronobacter sakazakii No unopened, distributed Abbott infant formulas have ever tested positive for Cronobacter sakazakii ABBOTT PARK, Ill., Sept. 14, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) has reached an agreement to resolve the previously disclosed investigation and lawsuit brought by the United States Department of Justice, as well as lawsuits filed by certain relators and the Attorneys General of several states, relating to Abbott's manufacturing and 2022 recall of powdered infant formula at its facility in Sturgis, Mich.